EGP-437 demonstrated better clinical performance than vehicle control, but did not meet its co-primary endpoints.
Scholar Rock – a biotechnology company focused on discovering and developing drugs that selectively target growth factors in the disease microenvironment – announced the publication of “Blocking extracellular activation of myostatin as a strategy for treating muscle wasting,” in Scientific Reports, the peer-reviewed, open-access journal published by Nature.
Anika announced a research collaboration with the Institute of Integrative Biology at the University of Liverpool to develop an injectable mesenchymal stem cell therapy for osteoarthritis.
Pfizer Inc. announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera (rituximab-EU), met its primary endpoint.
Cabozantinib provided a statistically significant and clinically meaningful improvement versus placebo in overall survival at the planned second interim analysis for the population of second-line and third-line patients enrolled in the CELESTIAL study.
Odonate Therapeutics Inc. announced that it has initiated CONTESSA, a multinational, multicenter, randomized, Phase 3 study of tesetaxel in patients with locally advanced or metastatic breast cancer.
The DUO study showed statistically significant PFS improvement for duvelisib versus standard of care treatment ofatumumab.
For the pharmaceutical industry, 2016 brought new blockbusters onto the market to ease the pain of patent expirations.
The pharma landscape has significantly evolved in the last decade, especially when it comes to clinical trials.
Fueled by a desire for innovation and new medical breakthroughs, the biotech industry continues to enjoy substantial growth due to increased investment in R&D.
